Provided By GlobeNewswire
Last update: May 9, 2025
Initial proof-of-concept data from the ongoing BBI-355 Phase 1/2 POTENTIATE trial in patients with oncogene-amplified cancers anticipated in the second half of 2025
Read more at globenewswire.comNASDAQ:BOLD (8/1/2025, 8:23:48 PM)
1.16
-0.03 (-2.11%)
Find more stocks in the Stock Screener